Streetbeat News

Stock Prices

WINT

Windtree Therapeutics Inc (NASDAQ:WINT) shares dropped 20% to $0.32 after announcing a 1-for-18 reverse stock split effective April 19, 2024, to comply with Nasdaq's minimum bid price requirement. The split aims to increase the market price per share without changing ownership percentages. Windtree Therapeutics has seen an 87.55% decline year to date, underperforming its historical averages. The stock's Relative Strength Index is at 50.46, indicating neutral market conditions.

Portfolio Pulse from Henry Khederian

April 18, 2024 | 5:27 pm

WINT

Windtree Therapeutics' shares are trading lower following the company's approval of a 1-for-18 reverse stock split.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 5:23 pm

LAC

Lithium Americas Corp. (NYSE:LAC) shares dropped after announcing a $275 million public offering of 55,000,000 common shares at $5.00 each. The proceeds are aimed at advancing the Thacker Pass lithium project in Nevada. Despite the current dip, analysts have a positive outlook with an average 12-month price target of $7.25, suggesting potential upside.

Portfolio Pulse from Erica Kollmann

April 18, 2024 | 5:17 pm

CEG

Smart money investors have shown a significant interest in Constellation Energy (NASDAQ:CEG) options, with a bearish stance overall. Benzinga's options scanner revealed 8 unusual trades, indicating a mixed sentiment but leaning towards bearish with 62% bearish and 37% bullish trades. The trades suggest a target price range of $180 to $195 for CEG in the next three months. The largest trades include both calls and puts, with a notable bearish call at a strike price of $195 expiring on 01/17/25 and a bearish put at $180 expiring on 05/17/24. Constellation Energy, an energy solutions provider, has seen its stock price increase by 0.45% to $186.24, with an upcoming earnings report in 21 days. Analysts have a consensus target price of approximately $194.67 for CEG, with ratings from Morgan Stanley and Evercore ISI Group indicating a positive outlook.

Portfolio Pulse from Benzinga Insights

April 18, 2024 | 5:16 pm

GILD

Deep-pocketed investors show a divided sentiment on Gilead Sciences (NASDAQ:GILD), with options activity suggesting a bullish and bearish split. Significant options trades indicate a target price range of $65.0 to $75.0. Gilead's stock is currently down by -1.33%, with an RSI suggesting it may be oversold. An analyst from UBS maintains a Neutral rating with a target price of $75. The company's next earnings report is due in 7 days.

Portfolio Pulse from Benzinga Insights

April 18, 2024 | 5:16 pm

LGCOF

SSNLF

Samsung Group is implementing a six-day workweek for executives across all units to address business uncertainties, including currency depreciation, rising oil prices, and high borrowing costs, following disappointing results in 2023. This includes executives from Samsung Electronics Co. Ltd (OTC:SSNLF), which reported a significant operating loss in its semiconductor business. The move is part of a broader trend among South Korean conglomerates to navigate industry downturns and geopolitical risks.

Portfolio Pulse from Franca Quarneti

April 18, 2024 | 5:11 pm

DIA

IWM

JETS

QQQ

SPY

TSLA

Stocks rose on Thursday, with the S&P 500 aiming to end a losing streak, driven by corporate earnings. The iShares Russell 2000 ETF and U.S. Global Jets ETF saw gains, while Tesla dropped after a Deutsche Bank downgrade. The Philadelphia Fed Manufacturing Index beat expectations, but existing home sales fell. Commodities and Bitcoin rallied. Key ETFs like SPDR S&P 500, Dow Jones, and Invesco QQQ Trust posted gains, with notable stock movements in Discovery Financial Services, Capital One, and others ahead of earnings.

Portfolio Pulse from Piero Cingari

April 18, 2024 | 5:11 pm

SIX

B. Riley Securities analyst Eric Wold upgraded Six Flags Entertainment (NYSE:SIX) from Neutral to Buy and increased the price target from $30 to $31.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 5:10 pm

EXPE

Wedbush analyst Scott Devitt reiterates a Neutral rating on Expedia Group (EXPE) and maintains a $130 price target.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 5:08 pm

BNTC

Benitec Biopharma Inc (NASDAQ:BNTC) reported positive interim clinical data from its BB-301 Phase 1b/2a study in Oculopharyngeal Muscular Dystrophy (OPMD), showing improvements in swallowing functions without severe side effects. Additionally, the company announced a $40 million PIPE financing, leading to a 24% increase in its stock price.

Portfolio Pulse from Vandana Singh

April 18, 2024 | 5:04 pm